by Lucy Prior | Sep 4, 2023 | VHH Resources, VHHs
On the Origin of VHHs: Student serendipity and coincidental camels At Isogenica, we’re experts in discovering and developing VHHs – small format single chain antibodies. Unlike conventional IgG antibodies from humans or mice, VHHs (also known as nanobodies) are...
by Philippa Shelton | Aug 11, 2023 | VHH Resources, VHHs
From monoclonals to bi-specifics: Harnessing the transformative power of VHHs to supercharge IgG therapeutics Since their discovery over thirty years ago, monoclonal antibodies (mAbs) based on Immunoglobulin G (IgG) have transformed the diagnosis and treatment of many... by Philippa Shelton | Sep 4, 2022 | CAR-T, VHH Resources
Advantages of using VHH antibodies for CAR engineering Since the first anti-CD19 CAR-T cell therapy was approved in 2017, there’s been an explosion of interest in using engineered immune cells to treat cancer. CAR constructs consist of an external antibody-based...